Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Amicus Therapeutics, Inc. (FOLD)

11.09   0.18 (1.65%) 03-31 16:00
Open: 11.03 Pre. Close: 10.91
High: 11.21 Low: 11
Volume: 2,108,405 Market Cap: 3,135(M)

Technical analysis

as of: 2023-03-31 4:18:49 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 14.8     One year: 16.16
Support: Support1: 10.8    Support2: 8.98
Resistance: Resistance1: 12.67    Resistance2: 13.84
Pivot: 11.25
Moving Average: MA(5): 11.1     MA(20): 11.4
MA(100): 12.08     MA(250): 10.75
MACD: MACD(12,26): -0.4     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 25.1     %D(3): 24.7
RSI: RSI(14): 38.7
52-week: High: 13.84  Low: 5.9
Average Vol(K): 3-Month: 2,225 (K)  10-Days: 2,062 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ FOLD ] has closed above bottom band by 28.1%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.3 - 11.37 11.37 - 11.43
Low: 10.66 - 10.72 10.72 - 10.79
Close: 10.81 - 10.92 10.92 - 11.02

Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Sat, 01 Apr 2023
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at ... - Defense World

Tue, 28 Mar 2023
Bank of America Securities Analyst Gives Amicus Therapeutics a ... - Best Stocks

Mon, 27 Mar 2023
Bank of America Raises Amicus Therapeutics (NASDAQ:FOLD ... - MarketBeat

Mon, 27 Mar 2023
Amicus Therapeutics (FOLD) Announces European Commission ... -

Thu, 23 Mar 2023
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet? - Simply Wall St

Fri, 10 Mar 2023
Amicus Therapeutics is Now Oversold (FOLD) - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 283 (M)
Shares Float 204 (M)
% Held by Insiders 0.8 (%)
% Held by Institutions 105.9 (%)
Shares Short 18,090 (K)
Shares Short P.Month 19,650 (K)

Stock Financials

EPS -0.81
EPS Est Next Qtl -0.29
EPS Est This Year -1.33
EPS Est Next Year -1.02
Book Value (p.s.) 0.43
Profit Margin (%) -71.9
Operating Margin (%) -62.1
Return on Assets (ttm) -15.7
Return on Equity (ttm) -110
Qtrly Rev. Growth 7.1
Gross Profit (p.s.) 1.02
Sales Per Share 1.16
EBITDA (p.s.) -0.71
Qtrly Earnings Growth 0
Operating Cash Flow -167 (M)
Levered Free Cash Flow -94 (M)

Stock Valuations

PE Ratio -13.87
PEG Ratio 0.2
Price to Book value 25.2
Price to Sales 9.52
Price to Cash Flow -18.83

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.